Nadine Dohollou
A5012827037- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- BRCA gene mutations in cancer
- Radiomics and Machine Learning in Medical Imaging
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Research and Treatments
- Economic and Financial Impacts of Cancer
- Cancer Genomics and Diagnostics
- Global Cancer Incidence and Screening
- Colorectal Cancer Treatments and Studies
- Cancer survivorship and care
- Sarcoma Diagnosis and Treatment
- DNA Repair Mechanisms
- Estrogen and related hormone effects
- Health Systems, Economic Evaluations, Quality of Life
- Lung Cancer Treatments and Mutations
- Endometrial and Cervical Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Intraperitoneal and Appendiceal Malignancies
- Renal cell carcinoma treatment
- Phagocytosis and Immune Regulation
Polyclinique Bordeaux Nord Aquitaine
2016-2025
Polyclinique de Bordeaux-Tondu
2012-2024
Roche (Switzerland)
2021
Centre de Recherche en Cancérologie de Toulouse
2018
Clinique Pasteur
2018
Institut Bergonié
1995-2018
Inserm
2018
Institut Claudius Regaud
2018
Hôpital Tenon
2006-2017
Sorbonne Université
2006-2017
In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, clinically meaningful overall (OS) effect PD-L1-positive aTNBC. The KEYNOTE-355 trial adding pembrolizumab to chemotherapy aTNBC similar PFS effects. IMpassion131...
Deficiency in dihydropyrimidine dehydrogenase (DPD) enzyme is the main cause of severe and lethal fluoropyrimidine-related toxicity. Various approaches have been developed for DPD-deficiency screening, including DPYD genotyping phenotyping. The goal this prospective observational study was to perform exhaustive exome sequencing examine relationships between variants toxicity advanced breast cancer patients receiving capecitabine.Two-hundred forty-three were analysed (88.5% capecitabine...
<h2>Abstract</h2><h3>Background</h3> PAOLA-1/ENGOT-ov25 (NCT02477644) demonstrated a significant progression-free survival (PFS) benefit with maintenance olaparib plus bevacizumab versus placebo in newly diagnosed, advanced ovarian cancer. We report the prespecified main second (PFS2) analysis for PAOLA-1. <h3>Methods</h3> This randomised, double-blind, phase III trial was conducted 11 countries. Eligible patients had advanced, high-grade cancer and were response after first-line...
Abstract Background: ESR1 mutations are known drivers of resistance to first line aromatase inhibitors (AI)-based therapy in hormone receptor-positive (HR+) HER2- metastatic breast cancer (mBC) patients (pts), but their clinical actionability remains unknown. The randomized phase 3 PADA-1 trial aimed at evaluating the benefit associated with a switch fulvestrant-palbociclib upon detection rising mutation blood (bESR1mut) HR+ mBC pts treated by AI-palbociclib.. Methods: (NCT03079011),...
PURPOSE To assess the outcome and prognosis of adults with a neoplasm related to Ewing's sarcoma family tumors. PATIENTS AND METHODS The outcomes 182 consecutive patients older than 15 years or neoplasms managed from 1982 1992 were reviewed, without any selection according primary tumor site disease extension. RESULTS Of patients, 53 had evidence metastases at presentation (29%). Tumor size was greater 10 cm in 70 (41%). With median follow-up duration 66 months, 5-year overall survival (OS)...
The optimal application of maintenance PARP inhibitor therapy for ovarian cancer requires accessible, robust, and rapid testing homologous recombination deficiency (HRD). However, in many countries, access to HRD is problematic the failure rate high. We developed an academic test support treatment decision-making.Genomic Instability Scar (GIScar) was through targeted sequencing a 127-gene panel determine status. GIScar trained from noninterventional study with 250 prospectively collected...
Eribulin can represent a therapeutic alternative for patients with advanced breast cancer who have received at least one or two lines of anthracyclines-based chemotherapy and taxane therapy. In this observational study, we focused on long-responder patients, i.e. an objective response stability ≥ 6 months under eribulin to better characterize them. Metastatic (MBC) treated by in 2nd, 3rd 4th line between September 2011 June-2018 were included. The following parameters assessed: primary tumor...
Abstract Background Early access program (formerly cohort Temporary Authorization for Use) was granted trastuzumab deruxtecan (T‐DXd) in France based on DESTINY‐Breast01 trial which demonstrated its efficacy and safety HER2‐positive metastatic/unresectable breast cancer after ≥2 anti‐HER2‐based regimens received at metastatic stage. Method s This multicenter real‐world early included patients pretreated with least two lines of anti‐HER2 who T‐DXd 5.4 mg/kg intravenously monotherapy every 3...
Variations in clinical response to tamoxifen (TAM) may be related polymorphic cytochromes P450 (CYPs) involved forming its active metabolite endoxifen (ENDO). We developed a population pharmacokinetic (PopPK) model for and six metabolites determine clinically relevant factors of ENDO exposure. Concentration‐time data TAM 6 come from prospective, multicenter, 3‐year follow‐up study adjuvant (20 mg/day) patients with breast cancer, plasma samples drawn every months, genotypes 63 genetic...
PURPOSE A randomized unblinded phase III trial was designed to determine the ability of granulocyte-macrophage colony-stimulating factor (GM-CSF) accelerate recovery from febrile neutropenia induced by chemotherapy. PATIENTS AND METHODS total 68 patients with following chemotherapy defined as axillary temperature greater than 38 degrees C and absolute neutrophil count (ANC) less 1 x 10(9)/L were included. After stratification for high- low-risk induce neutropenia, treatment between GM-CSF at...
Abstract Background Ovarian cancer (OC) remains one of the most challenging and deadly malignancies facing women today. While PARP inhibitors (PARPis) have transformed treatment landscape for with advanced OC, many patients will relapse PARPi-resistant setting is an area unmet medical need. Traditional immunotherapies targeting PD-1/PD-L1 failed to show any benefit in OC. The CD47/TSP-1 axis may be relevant We aimed describe changes CD47 expression platinum therapy their relationship immune...
Advanced ovarian carcinoma in early progression (<6 months) (AOCEP) is considered resistant to most cytotoxic drugs. Gemcitabine (GE) and oxaliplatin (OXA) have shown single-agent activity relapsed cancer. Their combination was tested patients with AOCEP phase II study. Fifty pre-treated platinum–taxane received q3w administration of OXA (100 mg m–2, d1) GE (1000 d1, d8, 100-min infusion). Patient characteristics were a : median age 64 years (range 46–79),and 1 (84%) or 2 (16%) earlier lines...
5512 Background: Nintedanib, an oral inhibitor of VEGF-FGF-PDGF receptors, has been shown to prolong progression-free survival (PFS) when added adjuvant chemotherapy after primary surgery (duBois A, Lancet Oncol 2015). CHIVA trial explored the role nintedanib in combination with NACT. Methods: Patients (pts) FIGO stage IIIC-IV chemotherapy-naive AEOC considered as unresectable laparoscopic evaluation were randomized (2:1) be treated 3 4 cycles (cy) carboplatin (AUC 5 mg/mL/min) and...
Abstract Purpose: This study investigates changes in CD8+ cells, CD8+/Foxp3 ratio, HLA I expression, and immune coregulator density at diagnosis upon neoadjuvant chemotherapy (NACT), correlating with clinical outcomes. Experimental Design: Multiplexed profiling cell clustering analysis were performed on paired matched ovarian cancer samples to characterize the tumor microenvironment (iTME) under NACT patients enrolled CHIVA trial (NCT01583322). Results: Several (IC) subsets coregulators...